Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Copaxone Patent Suit: Is Teva Really Sure It Wants To Win The Case?

Executive Summary

The bench trial in Teva Pharmaceutical USA Inc.'s Copaxone (glatiramer) patent infringement suit against Mylan Pharmaceuticals Inc. and Sandoz Inc. concluded on Sept. 21 and the parties now await a decision by the judge. If Teva is successful, it may end up asking itself what a victory in this patent battle would cost in the broader war on biosimilars.

You may also be interested in...

Teva’s Copaxone Patent Win Delivers Bigger Blow To Sandoz Than Mylan

Sandoz, which has first to file on the generic, may have the most to lose after federal judge finds that Mylan and Sandoz ANDAs for generic Copaxone infringe all the claims in Teva’s patents, the latest of which expires in September 2015. FDA now has more time to review the ANDAs without pressure.

New Teva CEO’s Initial Priorities Are Manufacturing, Copaxone, R&D

Teva’s new CEO, Jeremy Levin, has been emphasizing manufacturing efficiency, global compliance and a more focused R&D structure in initial comments to Wall Street.

Mylan Exudes Confidence About Plan For Biogenerics

At a Feb. 21 investor day, Mylan discussed its long-term goals for launching several biosimilars, as well some hard-to-reproduce generic offerings.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts